Key result
Replacing contemporary-sensitive with high-sensitivity cTnI immunoassays reduced total cTnI tests by >10%, 3- and 4-sample collections by 61% and 73%, and CK-MB testing costs by 99.8%.
Why the study?
Despite evidence that high-sensitivity cardiac troponin immunoassays outperform contemporary-sensitive methods, some clinicians remain hesitant to implement them into routine clinical practice.
Does replacing contemporary-sensitive with high-sensitivity cardiac troponin I immunoassay improve efficiency and reduce costs in the emergency department?
Observational
Does replacing contemporary-sensitive with high-sensitivity cardiac troponin I immunoassay improve efficiency and reduce costs in the emergency department?
Implementing high-sensitivity cardiac troponin I testing in the emergency department significantly reduces laboratory workload, unnecessary testing, and associated costs compared to contemporary assays.
BACKGROUND: Although unquestionable evidence has been provided that high-sensitive (HS) cardiac troponin (cTn) immunoassay outperform the former contemporary-sensitive techniques, some clinicians are still hesitant to implement HS methods in routine clinical practice. This study was hence planned to evaluate the impact of replacing a contemporary-sensitive with HS cTnI immunoassay on hospital and laboratory workload. METHODS: Information on the total number of cTnI tests ordered, total number of blood samples collected, total number of CK-MB tests ordered, number of patients with the first HS-cTnI value below the limit of detection (LoD) and cumulative HS-cTnI values was extracted from the local hospital information system for the semesters before and after the HS method was introduced. RESULTS: Although the total emergency department (ED) visits modestly increased after introducing HS-cTnI, the number of total cTnI tests declined by over 10%. A substantial reduction of single-sample test requests was noted, accompanied by a considerable decline of 3- and 4-sample collections (i.e., -61% and -73%, respectively). A high percentage of patients (27.5%) displayed HS-cTnI values <LoD at admission, thus allowing safe discharge. The introduction of HS cTnI immunoassay was effective to collapse the number of CK-MB test requested and also generated favorable return of investment for the part of laboratory budget concerning cTnI testing (-3.2% of total costs for cTnI and -99.8% of total costs for CK-MB). CONCLUSION: The results of this study show substantial organizational and economic benefits by replacing contemporary-sensitive with HS cTnI immunoassays. (www.actabiomedica.it).
No takes yet. Share an insight, caveat, or question.
Aloe et al. (2019) conducted an observational in Emergency department patients requiring cardiac troponin testing. High-sensitivity cardiac troponin I (HS-cTnI) immunoassay vs. Contemporary-sensitive cTnI immunoassay was evaluated on Hospital and laboratory workload (test volumes and costs). Replacing contemporary-sensitive with high-sensitivity cTnI immunoassays reduced total cTnI tests by >10%, 3- and 4-sample collections by 61% and 73%, and CK-MB testing costs by 99.8%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: